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Available online 25 May 2005950Cancer immunotherapy has been extensively attempted by gene transfer of cytokines with viral
vectors. In this work, we compared the therapeutic effects of interleukin 12 and 15 (IL-12 and IL-15)
genes transferred to tumor cells or to dendritic cells (DCs), which were subsequently injected into
established tumors. For this purpose, we used viral vectors based on simian virus 40 (rSV40).
Importantly, we observed that nonmatured DCs infected with rSV40 vectors remained phenotypi-
cally immature. Infection of CT-26 tumor cells with rSV40 expressing IL-12 (rSVIL-12) or IL-15 (rSVIL-
15) failed to inhibit tumor development. In contrast, the intratumoral administration of syngeneic
DCs transduced with rSVIL-12 or rSVIL-15 was associated with a strong antitumor response; up to
40% tumor remissions were achieved with DCs transduced by rSVIL-12 and 73% with DCs
expressing IL-15. This antitumor effect correlated with the in vivo priming of tumor-specific CD8+ T
lymphocytes. Depletion studies showed that rSVIL-15-mediated antitumor efficacy was mediated
mainly by CD8+ T lymphocytes and NK cells. We conclude that (i) SV40-derived vectors are an
advantageous alternative to transduce genes into DCs and (ii) DCs transferred with IL-15 have an
enhanced capability to induce curative antitumor immunity when injected into malignant lesions.Key Words: SV40, gene therapy, dendritic cells, IL-15, IL-12, colon carcinoma CT26 cellsINTRODUCTION
Tumor gene therapy with immunostimulatory cytokines
has been successfully carried out in animal models with
recombinant viruses [1,2]. The most successful strategies
involve in vivo or in vitro transfection of tumor cells, as
well as intratumoral injection of cytokine gene-trans-
duced dendritic cells (DCs) [3–6]. However, results
obtained in phase I clinical trials have not been as
effective as the promising results observed in animal
models [7,8]. Therefore further research is required to
improve the effect of the protocols used so far.
Recently, simian virus 40 virus (SV40) has been
modified to be a replication-deficient gene therapy vector
[9–12]. SV40 has a doubled-stranded circular DNA of 5.2
kb [11,13]. Removal of the large T antigen gene renders
recombinant SV40 viruses (rSV40) replication-deficientand nononcogenic, decreases SV40 immunogenicity,
and generates free space in the SV40 genome to clone
transgenes [9,11]. rSV40 vectors have been used to drive
the expression of different therapeutic genes for the
treatment of Crigler–Najjar syndrome [14] and liver
cirrhosis (M. Vera et al., submitted for publication), for
modification of hematopoietic stem cells [15], or for
immunization protocols against HIV or HBV [16–18].
However, rSV40 has not been reported in antitumor
gene therapy.
Interleukin 12 (IL-12), a heterodimeric monokine
produced by activated macrophages and DCs, is one of
the most frequently used cytokines in cancer gene
therapies [5]. IL-12 has the ability to stimulate both
the innate and the adaptive immune response. In
addition, the antitumoral effect of IL-12 is mediatedMOLECULAR THERAPY Vol. 12, No. 5, November 2005
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which are involved in the inhibition of tumor angio-
genesis [19,20]. The major drawback of IL-12 as an
antitumor agent is the toxicity due to the hyperproduc-
tion of IFN-g when large amounts of IL-12 are expressed
[21]. IL-15 belongs to the 4-a-helix bundle family of
cytokines that binds receptors with IL2Rh and gc chains
[22,23]. IL-15 is produced by activated DCs, monocytes/
macrophages, or nonlymphoid cells and is a critical
cytokine in the development, homeostasis, and activa-
tion of the innate immune response [22,24–29]. IL-15
induces the differentiation of NKT cells and stimulates
NK cells to proliferate and secrete cytokines such as IFN-
g and GM-CSF [24,30]. Also, IL-15 is a critical growth
factor to initiate T cell division in vivo and inhibits
activation-induced T cell death [31,32]. This function is
being exploited for adoptive T cell therapy and other
strategies of immunotherapy [4]. Another important role
recently ascribed to IL-15 is the induction of proin-
flammatory cytokine secretion from DCs whose auto-
crine effect seems to be essential for inducing CD8+-
dependent Th1 immune responses in mice [33]. Den-
dritic cells are professional antigen-presenting cells
capable of activating an adaptive immune response
[34] and cells of the innate immune system such as
NK and NKT cells [35,36]. For these reasons, they have
been successfully used as vectors in vaccination and
therapy protocols [37,38]. One of the approaches to
increase the effectiveness of DCs in inducing therapeutic
immunity is to improve their ability to biosynthesize
lymphocyte-attracting chemokines or immunostimula-
tory cytokines such as IL-12 or IL-15.
In this report, IL12 and IL15 gene transfer was achieved
with recombinant SV40 vectors. We compared the anti-
tumor effectiveness of IL-12, IL-15, or their combination
when transduced into tumor cells or into DCs prior to
their injection inside the tumor. SV40 vectors are able to
infect CT26 murine colon carcinoma cells and DCs.
Importantly, we found that the non-mature state of DCs
does not change upon rSV40 infection. We show that
intratumorally injected DCs engineered to express IL-15
have the capacity to induce the rejection of experimental
colon carcinoma tumors and that this effect is principally
mediated by CD8+ T lymphocytes and NK cells, but also
by CD4+ T lymphocytes.
RESULTS
Generation of rSV40 Vectors Expressing Functional
Murine IL-12 and IL-15
We cloned the cDNAs of murine IL-12 or murine IL-15
into pSL-4pL [12], a Tag-deleted SV40 vector, to generate
prSVIL-12 (Fig. 1A) and prSVIL-15 (Fig. 1B). In the case
of IL-12, the cDNAs encoding the subunits of the
heterodimer, p35 and p40, were separated by an internal
ribosomal entry site [39]. We produced recombinantMOLECULAR THERAPY Vol. 12, No. 5, November 2005
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amplified them three times in COS-1 cells [12]. In
addition, we generated a recombinant SV40 virus
expressing luciferase (rSVLuc) as described previously
[12]. We titrated all viruses by a quantitative PCR that
amplifies the capsid genes [12]. Titers from 5  1010 to
1  1011 viral particles/ml were routinely obtained.
Contamination of the stocks with revertant wild-type
SV40 was not detected ([12] and data not shown).
We detected expression of IL-12 (Fig. 1C) or IL-15 (Fig.
1D) readily by immunofluorescence of CV-1 or COS-1
cells infected with rSVIL-12 or rSVIL-15, respectively.
ELISA quantification of IL-12 (Fig. 1E) indicated that
rSVIL-12 infection produced lower amounts of IL-12 than
other reported recombinant viruses such as adenovirus
([39] and data not shown). We assessed functionality of
rSV40-expressed IL-12 and IL-15 by measuring the
production of IFN-g from murine splenocytes stimulated
with the supernatant of COS-1 cells infected with rSVIL-
12 or rSVIL-15 (Fig. 1F). In contrast with the rSVIL-12-
and rSVIL-15-infected cells, the supernatants obtained
from rSVLuc-infected cells did not induce the expression
of IFN-g. Therefore, rSVIL-12 and rSVIL-15 express and
secrete significant amounts of biologically active IL-12
and IL-15 proteins. It cannot be ruled out that these
cytokines are not secreted but are being released from the
cells due to cell turnover. However, no cell damage was
observed upon infection.
rSV40 Vectors Infect CT26 Cells and DCs
Even if SV40 viruses infect with a broad host range [9],
we wanted to verify transduction of tumor cells and
DCs. Infection of DCs is an important issue as non-
dividing cells are not infected by many nuclear viruses
and viruses that enter DCs could be phagocytosed and
presented to the immune system as targets. We first
used rSVLuc and rSVIL-12 to infect DCs and we detected
expression of luciferase and IL-12 transgenes by immu-
nofluorescence (Fig. 2A). Mock-infected cells did not
show any fluorescence (data not shown). Subsequently,
we used rSVIL-12 or rSVIL-15 as reporter vector to study
the efficacy of transgene expression in the murine colon
cancer cell line CT26 or in DCs. We used the super-
natants of CT26 or human DCs (hDCs) infected with
rSVLuc, rSVIL-12, or rSVIL-15 to stimulate murine
splenocytes in which IFN-g production was detected by
ELISA. Note that we used hDCs instead of murine DCs
to avoid the background produced by factors secreted by
murine DCs that activate murine IFN-g production. We
detected similar amounts of IFN-g from the supernatants
of DCs infected with rSVIL-12 or rSVIL-15 (Fig. 2B). IFN-
g production in these cases was lower than in spleno-
cytes stimulated with the supernatant of COS-1 infected
cells (compare Figs. 1F and 2A), in which replication of
rSV40 vectors allows higher expression levels of the
transgenes. Also, the production of IL-12 from CT26 and951
FIG. 1. rSVIL-12 and rSVIL-15 expression. Schematic representations of (A) rSVIL-12 and (B) rSVIL-15 genomes. Murine IL-12 and IL15 coding sequences were
cloned under the SV40 early promoter (EP) of a Tag-deleted SV40 plasmid to generate prSVIL-12 and prSVIL-15, respectively. These plasmids express SV40 capsid
genes from the SV40 late promoter (LP) and contain polyadenylation sequences (pA). Transfection of these plasmids into COS-1 cells allows amplification of the
genome, which is packaged into the capsid proteins. Immunodetection of IL-12 and IL-15 in (C) rSVIL-12- and (D) rSVIL-15-infected cells. CV-1 or COS-1 cells were
infected with these viruses or infected with rSVLuc as a negative control (mock). Seventy-two hours after infection both cytokines were detected by
immunofluorescence. (E) Analysis of IL-12 secretion. Supernatants of rSVIL-12- or rSVLuc-infected COS-1 cells were analyzed by ELISA 72 h after infection. The assay
recognizes the heterodimeric form of IL-12. Bars indicate standard deviations. The asterisk indicates significant differences ( P b 0.05). (F) Analysis of IL-12 and IL-15
functionality. The supernatant of splenocytes stimulated for 48 h with the supernatant of COS-1 cells infected with rSVIL-12, rSVIL-15, or rSVLuc was analyzed for the
presence of IFN-g using an ELISA. Bars indicate standard deviations. Asterisks indicate significant differences ( P b 0.05).
ARTICLE doi:10.1016/j.ymthe.2005.03.030DCs is lower in rSV40-infected cells than in cells
infected with adenoviral vectors (data not shown).
Furthermore, adenovirus infection of DCs induces par-
tial DC maturation [40], which may decrease their
ability to capture tumor antigens. To analyze if rSV40
infection could induce DC maturation, we mock trans-
duced hDCs or transduced them with rSVLuc and
analyzed maturation-related surface markers by FACS
36 h after infection. We found no significant changes in
the surface expression of CD80, CD86, CD40, CD11c,
MHC class I, and MHC class II before or after rSV40
infection (Fig. 2C), suggesting that DCs do not mature
after rSV40 infection. A similar result was obtained with
murine DCs (data not shown). This could represent an
advantage of using rSV40 vectors instead of adenoviral
vectors to modify DCs.952Lack of Antitumor Effect upon CT26 Infection with
rSVIL-12 and/or rSVIL-15
To evaluate the antitumor efficacy of rSV40 vectors in a
model of murine colorectal adenocarcinoma in syngeneic
Balb/C mice, we first transduced CT26 cells with 100 viral
particles per cell of rSVIL-12, rSVIL-15, or rSVLuc. Mock-
infected CT26 cells were used as a control. Forty-eight
hours postinfection, we injected groups of 8–10 mice
subcutaneously at the right flank with 5  105 infected
CT26 cells per mouse. We monitored tumor growth every
3 days. Five to 6 days after injection we detected tumor
nodules in all groups and no differences in tumor growth
were found between groups. Only 2 animals from the
rSVLuc control group and 1 from the rSVIL-15 group
showed tumor regression at day 10 (data not shown) and
complete tumor disappearance (Table 1). Following this,MOLECULAR THERAPY Vol. 12, No. 5, November 2005
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FIG. 2. Recombinant SV40 vector transduction of CT26 cells and human DCs (hDCs). (A) DCs were infected with rSVLuc (a–c) or rSVIL-12 (d–f). Cells were fixed
at 48 h postinfection and an immunofluorescence assay was carried out. Luciferase (a and c) or IL-12 (d and f) expression is shown in green. DNA has been
stained with DAPI, which shines blue under UV light (b and e). An overlapping of the green and blue signals is also shown (c and f). (B) IFN-g expression from
CT26 and hDCs infected with rSVIL-12 or rSVIL-15. CT26 cells and hDCs were infected with an m.o.i. of 100 viral particles of rSVIL-12, rSVIL-15, or rSVLuc as a
negative control. Seventy-two hours after infection the supernatants of both cell types were used to stimulate murine splenocytes whose IFN-g production was
measured by ELISA. Bars indicate standard deviations. Asterisks indicate significant difference ( P b 0.05). (C) Surface marker analysis of hDCs infected with rSV40.
hDCs were mock infected or infected with rSVLuc. Thirty-six hours after infection cells were stained with PE- or FITC-labeled antibodies that recognize CD11c,
HLA Class I, HLA Class II, CD40, CD80, or CD86 and analyzed by FACS. Similar expression of these surface markers is detected in mock-infected or rSVLuc-
infected DCs. In each graph, upper numbers indicate the mean fluorescence and lower numbers indicate the percentage of positive cells.
ARTICLEdoi:10.1016/j.ymthe.2005.03.030we decided to test the antitumoral effect of rSV40
infections in preestablished CT26 tumors of 5 mm
diameter obtained by previous injection of 5  105 CT26
cells per mouse. In this experiment we mock treated a
group of mice as a negative control or infected them
intratumorally with 2  109 pfu of a first-generation
adenoviral vector driving the expression of IL-12 (AdIL-TABLE 1: Tumor regression analysis of subcutane
Saline rSVLuc rSVIL-12 rSVIL-15 3  rSVL
Pretreatment 0/10 2/10 0/10 1/10
Intratumoral
treatment
0/20 1/10 1/10 1/5 2/15
CT26 cells were infected before (pretreatment) or after (intratumoral treatment) subcutaneous i
or transduced with 100 viral particles per cell of rSVIL-12, rSVIL-15, or rSVLuc. Forty-eight hours
cells per mouse and tumor growth was monitored. For the treatment, 5  105 CT26 cells were
infected (saline) or infected intratumorally with a first-generation adenoviral vector driving t
respectively. Intratumoral injections were also given once or three times every other day (3) w
combination of the last two vectors (rSVIL-12/15). Tumor growth was monitored. Values show
animals treated. Statistical analysis indicates rSV40 vectors are not efficient compared to AdIL-
MOLECULAR THERAPY Vol. 12, No. 5, November 2005
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Negative control adenovirus was not included as it has
been reproducibly shown that it has no effect [2,39]. In
addition, we infected seven different groups of five or six
mice intratumorally with 1  109 viral particles of rSVLuc,
rSVIL-12, or rSVIL-15. As shown in Table 1, groups received
one or three doses of these vectors every other day fromous CT26 nodules infected with rSV40 vectors
uc 3  rSVIL-12 3  rSVIL-15 3  rSVIL-12/15 AdIL-12
2/15 3/15 4/20 4/6
noculation into Balb/C mice. For the pretreatment, CT26 cells were mock transduced (saline)
postinfection, 10 mice per group were subcutaneously injected with 5  105 infected CT26
injected per mouse. Seven to ten days postinjection, tumors of 5 mm diameter were mock
he expression of IL-12 (AdIL-12) as negative and positive control for therapeutic efficacy,
ith rSV40 vectors expressing luciferase (rSVLuc), IL-12 (rSVIL-12), or IL-15 (rSVIL-15) or the
n indicate the number of animals in which tumor nodules regressed vs the total number of
12 treatment in this tumoral setting.
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ARTICLE doi:10.1016/j.ymthe.2005.03.030day 9. Another group received 1  109 viral particles of a
mixture of rSVIL-12 and rSVIL-15 three times, as it has
been demonstrated that the combination of IL-12 and IL-
15 has a synergic effect on the production of IFN-g [41]. To
analyze synergism, we used half a dose of each virus so the
total amount of virus was kept constant. We carried out
three independent experiments and the results are sum-
marized in Table 1. Statistical analysis indicates that none
of the treatments using rSV40 vectors is as efficient as
AdIL-12 treatment, which induced tumor regression in
66% of cases. Treatment with three doses of rSVIL-12 or
rSVIL-15 resulted in one rejection of five treated tumors at
best. These results indicate that rSV40 vectors are less
efficient than first-generation adenoviruses for the treat-
ment of this type of tumor model.
Antitumor Effect of Dendritic Cells Infected with
rSVIL-12 or rSVIL-15
Dendritic cells are the main antigen-presenting cells of
the immune system and they have been widely used as
target cells for gene therapy. DCs transduced with virus
expressing IL-12 have been shown to be an efficient
antitumor weapon in preclinical models [42,43].
Recently, it has been shown that IL-15 plays an
important role in the interaction of DCs with the
effector CD8+ T lymphocytes at the start of an adaptive
immune response [33]. For this reason, we studied the
efficacy of rSV40 vectors as tools to transfer IL-12 or IL-
15 genes into DCs for tumor treatment. We obtained
DCs from the bone marrow of Balb/C mice cultured for
7 days in the presence of GM-CSF and IL-4. At day 7, we
infected the DCs with 100 particles per cell of rSVIL-12,
rSVIL-15, or both viruses. We used rSVLuc and mock-
infected DCs as controls. We studied five different
groups of six to eight mice in parallel (Table 2). Each
mouse developed a CT26 tumor nodule of approxi-
mately 5 mm diameter, which we injected with 5  105
DCs infected with SV40 36 h previous to inoculation.
We then monitored tumor growth (Fig. 3). We repeated
this experiment three times for all groups with the
exception of the rSVIL-12 + rSVIL-15 group, for which it
was performed only twice. We found that treatment
with unmodified DCs or DCs infected with rSVLuc
showed a significant antitumor effect compared to theTABLE 2: Tumor regression analysis of subcutaneous CT2
Saline DC
Intratumoral non-mature DCs 2/19 5/22
Intratumoral mature DCs 1/6 1/6
Intravenous non-mature DCs 0/6
CT26 tumor nodules of 5 mm diameter were injected intratumorally or intravenously with non-
with DCs matured with LPS prior to intratumoral injection (intratumoral mature DCs). The DCs
and rSV-15 (rSVIL-12/15) for 36 h. Following this, tumor growth was monitored. Values shown
injected animals. Statistical analysis indicates that intratumoral injection of mature DCs or intr
954saline-treated group (Figs. 3A and 3B). DCs infected with
rSVIL-12 or rSVIL-12 + rSVIL-15 showed higher efficacy
(Figs. 3A and 3B). Surprisingly, a significantly higher
antitumor treatment was obtained with DCs infected
with rSVIL-15, yielding 73% complete tumor remission
(Figs. 3A and 3B). Accordingly, DCrSVIL-15 treatment
prolonged survival of CT26 tumor-bearing mice com-
pared to control groups (Fig. 3B). Importantly, the cured
mice in every group developed immune memory as
indicated by resistance to rechallenge at day 21 after
tumor regression (Fig. 3C).
To evaluate the role of maturation in the efficacy of
DCs infected with rSV40, we induced the maturation of
infected DCs by treatment with lipopolysaccharide (LPS)
prior to intratumoral injection. Despite data showing
that mature DCs stimulate T cells with higher efficiency,
we obtained no significant antitumor effect (Table 2).
Subsequently, we evaluated the antitumor effect of
systemically administered nonmatured DCs infected
with rSVLuc or rSVIL-15. We injected the cells via the
tail vein of Balb/C mice bearing subcutaneous CT26
tumors and evaluated tumor growth. As shown in Table
2, none of the treatments displayed any efficacy. As a
whole, these results suggest that antitumoral efficacy is
obtained only when DCs load antigens at the tumor
site, as non-mature DCs capture antigens more effi-
ciently than mature DCs.
Treatment with rSVIL-15-Infected DCs Induces
Tumor-Specific IFN-g-Producing CD8+ Lymphocytes
and a CTL Response
CD8+-specific immune response has been shown to play
an essential role in CT26 tumor rejection [2,39,42]. Thus,
we used ELISPOT to analyze the CT26 specific CD8+
immune response developed in mice that showed tumor
rejection after treatment with the rSV40-infected DCs.
We rechallenged these animals subcutaneously with 5 
105 CT26 cells 3 weeks after tumor rejection and
sacrificed them 15 days after rechallenge. We stimulated
splenocytes from these animals with antigen-loaded P815
cells or P815 cells alone as a negative control. As an
antigen, we used a previously described CT26-derived
epitope (AH1) [44] presented by H-2Dd. All treated groups
showed AH1-specific IFN-g-producing CD8+ lympho-6 nodules treated with DCs infected with rSV40 vectors
rSVLuc rSVIL-12 rSVIL-15 rSVIL-12/15
6/20 9/22 16/22 6/13
2/6 1/6 1/6
1/7 2/7
mature DCs (intratumoral non-mature DCs or intravenous non-mature DCs, respectively) o
used were either mock infected (DC) or infected with rSVLuc, rSV-12, rSV-15, or both rSV-12
indicate the number of animals in which tumor nodules were rejected vs the total number o
avenous injection of non-mature DCs is not efficient for treatment in this tumoral setting.
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fy
FIG. 3. Effect of intratumoral injection of non-
mature DCs infected with rSV40 vectors. (A)
Tumor growth analysis. Tumor nodules pro-
duced by subcutaneous injection of 5  105
CT26 cells in Balb/C mice were mock injected
(saline) or injected intratumorally with 5  105
mock-infected DCs (DCs) or DCs infected with
rSVLuc (DCrSVLuc), rSVIL-12 (DCrSVIL-12),
rSVIL-15 (DCrSVIL-15), or the combination of
the last two viruses (DCrSVIL15/12). The per-
centage of survival is shown at the top right of
each independent graph. The results shown
were obtained in three independent experi-
ments. (B) Long-term survival analysis. Plot of
the percentages of survival rate of the groups
shown in A. Significant differences are indicated
with an asterisk ( P b 0.05). Nonsignificant
differences are also indicated (ns). (C) Rechal-
lenge analysis. Tumor growth after subcutane-
ous injection of CT26 cells in control animals or
animals that had rejected CT26 tumor nodules
after intratumoral injection of saline solution,
mock-infected DCs (DC), or DCs infected with
rSVLuc (DCrSVLuc), rSVIL-12 (DCrSVIL-12),
rSVIL-15 (DCrSVIL-15), or the combination of
both (DCrSVIL15/12). Values shown indicate
the animals in which tumor nodules were
detected vs the total number of animals
injected.
ARTICLEdoi:10.1016/j.ymthe.2005.03.030cytes, in contrast with the control group, which experi-
enced tumor progression. As expected, the amount of
specific lymphocytes correlated positively with the effi-
cacy of the antitumoral treatment. Therefore, mice
treated with rSVIL-15-infected DCs significantly showed
the highest amount of specific spots (Fig. 4A). Moreover,
splenocytes harvested from mice treated with rSVIL-15-
infected DCs displayed a potent lytic activity against
CT26 cells or P815 cells pulsed with the AH1 peptide (Fig.
4B). This activity was lower in control splenocytes
obtained from untreated mice (Fig. 4B) or from mice in
the other experimental groups (data not shown). Specif-
icity of cytotoxicity was controlled against nonpulsed
P815 cells (Fig. 4B).MOLECULAR THERAPY Vol. 12, No. 5, November 2005
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tumor Efficacy of DCs Infected with rSVIL-15
Finally, we studied the involvement of different cell
populations in the antitumoral efficacy of rSVIL-15-
infected DCs. Thus, we studied the antitumoral effect in
mice depleted of CD8+, CD4+ lymphocytes or NK cells.
We treated mice with purified specific monoclonal anti-
bodies against CD8+ or CD4+ molecules or with anti-
asialo GM1, used for the depletion of NK cells. We then
applied DC treatment to CT26 tumors and evaluated
tumor growth. Depletion of CD8+ and NK cells before
tumor treatment with rSVIL-15-infected DCs eliminated
antitumor efficacy (Figs. 5A, 5D, and 5E). Furthermore,
CD4+-depleted mice showed no tumor remissions (Fig.955
FIG. 4. Intratumoral injection with DCs induces tumor-specific IFN-g-
producing CD8+ T cells and CTLs. (A) Quantitation of IFN-g-producing T
lymphocytes. Splenocytes from animals described for Fig. 3C were incubated
for 24 h in 96-well plates with mitomycin C-treated P815 control cells or P815
cells pulsed with AH1 peptide. The plot for the quantitation of the specific
spots developed with a biotinylated specific antibody against murine IFN-g
and streptavidin–peroxidase is shown. Bars indicate standard deviations. The
asterisk indicates a significant difference ( P b 0.05). (B) Analysis of cytolytic
activity. Splenocytes from control or DCrSVIL-15-treated animals described for
Fig. 3C were stimulated in vitro for 5 days with CT26 cells, in the presence of
IL-2 for the last 3 days. Splenocytes were then cultured for 5 h with 51Cr-
labeled CT26 cells or P815 cells alone or pulsed with AH1. Quantitation of 51Cr
release is shown with a ratio of effector cells to target cells (E:T) of 11 or 3.
ARTICLE doi:10.1016/j.ymthe.2005.03.0305C), although tumor growth in this group was slower
than in CD8+- and NK-depleted mice (Fig. 5A). This
suggests that CD4+ T cells have a role in antitumoralFIG. 5. Analysis of the requirement for
CD8+, CD4+ T lymphocytes or NK cells
in the antitumor effect of DCs infected
with rSVIL-15. Growth evaluation of
CT26 nodules (A) untreated or treated
with DCs infected with rSVIL-15 in (B)
Balb/C control mice or mice depleted of
(C) CD4+ T cells (aCD4), (D) CD8+ T
cells (aCD8), or (E) NK cells (aasialo
GM1).
956efficacy mediated by rSVIL-15-infected DCs. These results
indicate that CD8+ T lymphocytes and NK cells are the
main mediators of the antitumor effect observed in mice
treated with rSVIL-15-infected DCs.
DISCUSSION
One promising option in gene therapy against cancer is
the use of immune-modulating cytokines. Several
recombinant viral vectors—such as adenoviruses, retro-
viruses, or poxviruses—expressing therapeutic cytokines
have been used to treat neoplastic malignances in animal
models with widely differing results [45]. In this work we
analyzed the potential of recombinant SV40 viruses for
cancer immunotherapy using cytokine gene transfer.
rSV40 is a low-immunogenic vector that allows long-
term transgene expression and repeated administration
of the same vector ([11,46] and U. Arad et al., submitted
for publication). We compared the antitumoral effect of
rSV40 vectors that express functional IL-12 or IL-15 (Figs.
1, 2A, and 2B) in Balb/C mice with CT26 colon
adenocarcinomas using different experimental settings.
Infection of CT26 cells with rSVIL-12 and rSVIL-15
both in vitro and in subcutaneously implanted tumors
failed to inhibit tumor growth in Balb/C mice (Table 1).
This is in clear contrast with the potent antitumor effect
of adenoviruses encoding IL-12 after intratumoral injec-
tion of the vector in the same experimental model. It
seems possible that these differences are due to the low
levels of IL-12 expression obtained with rSV40 vectors
(Figs. 1E, 1F, and 2B). The development of modified
rSV40 vectors capable of expressing higher amounts of
transgene should overcome this problem.
In contrast to the poor antitumor response observed
after injection of SV40 vectors into the neoplastic nodule,
nonmatured DCs infected with rSVIL-12 or rSVIL-15 andMOLECULAR THERAPY Vol. 12, No. 5, November 2005
Copyright C The American Society of Gene Therapy
ARTICLEdoi:10.1016/j.ymthe.2005.03.030implanted intratumorally showed antitumor effect (Fig.
3, Table 2). Nonmatured DCs can be easily infected with
rSV40 vectors and maintain their phenotype after infec-
tion (Fig. 2C). In contrast, infection of DCs using
adenovirus or poxvirus has resulted in the partial
maturation of the DCs [40]. The preservation of the
phenotype of non-mature DCs after rSV40 infection
could be one advantage of this vector over other
recombinant vectors. Maturation of DCs should not
affect therapeutic effects when DCs have been preloaded
with tumor-derived antigens or when tumor antigens are
expressed from recombinant viruses. However, when
injected into the neoplastic nodule, mature DCs do not
load tumor antigens as efficiently as immature DCs and
this might explain why rSV40-transduced non-mature
DCs elicit more potent antitumor responses than
matured DCs infected with the same vector (Table 2).
The antitumor effect observed with rSVIL-15 was
stronger than that observed with rSVIL-12, even though
DCs infected with these vectors induce similar levels of
IFN-g (Fig. 2B). The analysis of the immune mechanism
behind the antitumor effect of SV40-transduced DCs
revealed that the stronger antitumor effect observed with
rSVIL-15 DCs correlates with a significantly higher
development of CD8+ CT26-specific T cells as shown by
the ELISPOT and CTL assays (Fig. 4). Furthermore,
according to selective in vivo depletion experiments, the
activity of CD8+ T cells and NK cells is an absolute
requirement for the therapeutic effect observed with
rSVIL-15-transduced DCs (Fig. 5). In agreement with
these data, IL-15 has been shown to sustain CD8+
memory T cells, to inhibit T cell apoptosis, to increase
NK cell cytotoxicity, and to activate NK cells to produce
several cytokines with antitumoral activity such as IFN-g,
GM-CSF, and TNF-a [24,30]. Results after CD4+ T cell
depletion also indicate a role for CD4+ cells in the
antitumor immunity elicited by rSVIL-15-transduced
DCs.
To our knowledge, this is the first report in which a
viral vector driving the expression of IL-15 has been used
to infect DCs to develop an antitumoral effect. We are
currently experimenting with the exact molecular role of
IL-15 when artificially released by DCs at the onset of the
antitumor immunity. Recently, experimental evidence
provided by Ruckert and co-workers [33] indicated the
essential role of IL-15 production by DCs in the develop-
ment and differentiation of CD8+ T cells. IL-15 derived
from DCs acts as a positive signal for DC activation to
promote and optimize DC/T cell interactions. Moreover,
IL-15 plays an autocrine role in DCs by enhancing
antigen presentation and costimulatory signals for T
cells. We believe that all these findings are operating in
our model because the generation of CT26-specific IFN-g-
producing CD8+ T cells was significantly increased in the
group of mice treated with rSVIL-15-infected DCs (Fig.
4A). Other mechanisms may act behind IL-15 function.MOLECULAR THERAPY Vol. 12, No. 5, November 2005
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production in splenocytes (Figs. 1F and 2B and data not
shown). Furthermore, recombinant IL-15 induces DC
maturation (data not shown). It has been described that
the IL-15/IL-15R interaction plays a critical role in the
activation of DCs and in the innate immune system. In
particular production of IL-12, IFN-g, and NO depends on
this interaction, since DCs obtained from g-subunit-
deficient or IL-2 receptor h-deficient mice failed to
produce these molecules [47]. Thus, the IL-15 produced
by the DCs transduced with rSV40-IL-15 might be acting
over the same DCs to induce the production of IL-12,
IFN-g, and NO, which could inhibit tumor development
directly.
The antitumor activity of IL-12 also relies on activa-
tion of NK and CD8+ T cells and on the induction of a
Th1 response [42]. Interestingly, the antitumor response
induced by DCs transduced with rSV40 encoding IL-12
was weaker than that observed with DCs infected with
rSVIL-15 or adenoviral vectors encoding IL-12 [42]. These
differences might be due to the lower levels of transgene
expression obtained with SV40 vectors and also to the
fact that IL-15 may enhance the immunostimulatory
properties of DCs more intensely than IL-12. Further-
more, co-infection of DCs with a mixture of rSVIL-12 and
rSVIL-15 showed no increased efficacy compared to the
administration of the same titer of each vector independ-
ently. Rather, the mixture of rSVIL-12 and rSVIL-15
showed an effect similar to that of the same amount of
rSVIL-12 alone. Thus, under the conditions of our
experiments, no synergism between IL-12 and IL-15
could be observed.
In conclusion our data suggest that SV40 is a novel
vector that can be employed to manipulate DC functions
and that rSVIL-15-transduced DCs may represent a useful
tool to induce strong antitumor responses.MATERIALS AND METHODS
Animal and cell lines. Six-week-old female Balb/C mice were purchased
from Harlan. All experiments with animals were performed following
guidelines from the institutional ethical commission. The monkey
kidney fibroblast COS-1 and CV-1 cells were obtained from the ECACC.
The murine colorectal adenocarcinoma CT26 was obtained from the
ATCC. All cell lines were cultured in DMEM, supplemented with 10%
fetal bovine serum (FBS), 1% penicillin–streptomycin, and 0.2 mM
glutamine. All tissue culture reagents were purchased from Gibco BRL/
Life Technologies.
Generation of DCs. Murine dendritic cells were obtained from Balb/C
bone marrow cells following a previously described protocol [42]. Briefly,
bone marrow cells were flushed from femurs of mice and differentiated for
7 days in culture with RPMI supplemented with 10% Myoclone FBS, 20
Ag/ml murine GM-CSF (Peprotech), and 20 Ag/ml murine IL-4 (Pepro-
tech). Flow cytometry was routinely used to characterize the DC surface
markers CD80, CD86, CD40, CD11c, H2KD, and 1AD (Pharmingen;
FACSCalibur, Becton–Dickinson). The resulting population was 80–90%
DCs as shown by staining with CD11c. Maturation of murine DCs was
achieved by incubation for 24 h with 1 Ag/ml LPS (Sigma). Human DCs
were obtained from healthy donors as previously described [48].957
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was generated and produced as described previously [12]. To generate a
recombinant SV40 virus with the murine IL-12 coding sequence (rSVIL-
12), pBS/IL-12 plasmid [39] was digested with SalI and NotI and the IL-
12 gene was cloned into the same restriction sites of pSL-4pL [12].
Generation of rSV40 with IL-15 cDNA (rSVIL-15) was performed by
digestion of pNGVL-3-mil15s with EcoRV and NotI and cloning of IL-15
sequences into pSL-4pL [12] digested with SmaI and NotI. All con-
structions were verified by restriction analysis. pSL-4pL-derived plasmids
contain a Tag-deleted SV40 genome and bacterial sequences, which were
excised with NotI. Both rSV40 genomes were gel extracted (Gel
Extraction Kit; Qiagen) and recircularized. rSVIL-12 and rSVIL-15 vectors
were produced and purified following the protocol described for rSVLuc
vectors [12]. rSV40 titer was determined by real-time quantitative PCR
[12].
Cell infection and transgene detection. CV-1 cells were grown on 12-
well plates and COS-1 cells were grown on four-chamber slides treated
with d-polylysine (Nunc). Both cell lines were infected at an m.o.i. of
100 viral particles/cell with rSVIL-12 or rSVIL-15. Seventy-two hours
after infection, cells were fixed and permeabilized, blocked overnight at
48C with serum from the host of the secondary antibody, and
immunostained with either 2 Ag/Al anti-murine IL-12 goat antibody
(Cell Science) or 1 Ag/Al anti-IL-15 rabbit antibody (Abcam). After a
wash with PBS, FITC-labeled rabbit anti-goat (Sigma) or goat anti-rabbit
(Dako) antibodies were used. Preparations were mounted with Vecta-
shield (Vector Laboratories) and analyzed in an Olympus inverted
fluorescence microscope. Immunofluorescence on DCs was performed
similarly but rSVLuc and rSVIL-12 were used for infection. Forty-eight
hours postinfection cells were fixed and luciferase and IL-12 were
visualized using 20 Ag/ml anti-Luc goat antibody (Promega) or 2 Ag/ml
anti-IL-12 goat polyclonal antibody (Abcam), respectively. The secon-
dary antibody was an FITC-labeled rabbit anti-goat (Dako). To detect
the secretion of IL-12 in rSVIL-12-infected cells, 5  105 COS-1 cells
were infected at an m.o.i. of 100 viral particles of rSVIL-12 or rSVLuc
as a negative control. Seventy-two hours after infection 100 Al (1/5) of
supernatant was assayed by ELISA to quantify IL-12 p70 production
(Pharmingen).
Cytokine functional assay. To study the functionality of recombinant IL-
12 and IL-15 produced from COS-1, CT26, or hDCs, cells were infected
with rSVIL-12, rSVIL-15, or rSVLuc, as a negative control. Three days after
infection, supernatants from infected cells were harvested and 50 Al was
used to stimulate 5  105 Balb/C mouse splenocytes for 48 h. One
microliter of medium from splenocytes stimulated with COS-1 cell
supernatant or 100 Al of medium from splenocytes stimulated with
CT26 or hDCs supernatant was assayed by ELISA to quantitate the
amount of IFN-g (Pharmingen).
Animal manipulation and tumor treatment. CT26 cells were infected
with rSVLuc, rSVIL-12, or rSVIL-15 or mock infected, as previously
described [12]. Thirty-six hours after infection, 5  105 cells per mouse
were injected subcutaneously into the right flank of Balb/C mice and
tumor growth was evaluated. Tumors were treated 9 days later, when
tumor diameter was about 5 mm. Treatment consisted in the intratumoral
injection of 50 Al of saline buffer with 1  109 viral particles of the
different rSV40 vectors or 5  105 murine DCs infected with 100 rSV40
particles per cell for 36 h. When DCs were infected with a mix of rSVIL-12
and rSVIL-15, a half dose of each virus was used. The same doses of
infected DCs were also injected in the tail vein in 200 Al of saline buffer.
Tumor growth was monitored by measuring two perpendicular tumor
diameters with a precision caliper. Several animals that eliminated the
tumor were subjected to a rechallenge with the same dose of CT26 cells
and sacrificed after 15 days for the analysis of the immune response by
ELISPOT and cytotoxicity assay. Animals were killed when the tumor
reached a size of 15 mm in diameter.
Depletion of lymphocytes. Five to six tumor-bearing mice per group were
depleted of CD4+ or CD8+ T lymphocytes by intraperitoneal injection of
100 Al of anti-CD4 or anti-CD8 ascitic fluids as previously described [49].958For NK depletion, 100 Al of anti-asialo GM1 (Wako) was administered
intraperitoneally as described [49]. Depletions were verified by FACS
analysis of peripheral blood mononuclear cells stained with fluoro-
chrome-tagged anti-CD3, anti-CD4, anti-CD8, or anti-Pan-NK (DX5)
(Pharmingen [49]).
ELISPOT and cytotoxicity assays. An ELISPOT was used to quantify IFN-
g-producing CD8+ T cells from the spleens of mice that had eradicated a
CT26 tumor and rejected a rechallenge with CT26 cells. Briefly, 5  105
splenocytes were incubated in triplicate with P815 cells alone or pulsed
with the H-2Ld-restricted peptide AH1 (SPSYVYHQF) [44] in plates
(Millipore) pretreated with a rat anti-murine IFN-g antibody (Pharmin-
gen). After 24 h of incubation in medium supplemented with horse
serum, the spots were developed with a rat biotinylated anti-murine IFN-g
antibody (Pharmingen), streptavidin–peroxidase (Roche), and DAB
(Sigma) and observed in a Nikon stereomicroscope [50]. Notice that horse
serum was used instead of FBS to avoid the immune response induced
against the FBS that was used to culture the DCs.
The cytotoxic response was analyzed by a conventional 51Cr assay.
Splenocytes were stimulated for 5 days with CT26 cells at a ratio of 10:1.
The medium was supplemented with 5 U/ml of IL-2 (Roche) for the last 3
days of incubation. 51Cr-containing P815, CT26, or P815 cells loaded with
the peptide AH1 were incubated with effector cells at different effector cell
vs target cell ratios and 51Cr release was allowed for 5 h and measured in a
gamma counter to calculate the percentage of specific release (TopCount;
Packard). All experiments were done in triplicate.
Statistical analysis. Expression levels were compared using ANOVA or t
tests. Tumor growth was evaluated individually, as mice can be grouped
only as responders and nonresponders. Survival curve data were analyzed
with a Kaplan–Meier test and statistical analysis was carried out with a log
rank test. ELISPOT and cytotoxicity assays were compared using ANOVA
followed by a Student–Newman–Keuls test. Differences were deemed
significant for a real a of 0.05. All statistical analysis was carried out with
SPSS v11.0 (SPSS, Inc.).
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